Joana Ramalho1, Mauricio Castillo2. 1. Centro Hospitalar de Lisboa Central, Lisboa, Portugal; University of North Carolina at Chapel Hill, Chapel Hill, NC, US. 2. University of North Carolina at Chapel Hill, Chapel Hill, NC, US.
Abstract
Traumatic brain injury (TBI) represents a significant public health problem in modern societies. It is primarily a consequence of traffic-related accidents and falls. Other recently recognized causes include sports injuries and indirect forces such as shock waves from battlefield explosions. TBI is an important cause of death and lifelong disability and represents the most well-established environmental risk factor for dementia. With the growing recognition that even mild head injury can lead to neurocognitive deficits, imaging of brain injury has assumed greater importance. However, there is no single imaging modality capable of characterizing TBI. Current advances, particularly in MR imaging, enable visualization and quantification of structural and functional brain changes not hitherto possible. In this review, we summarize data linking TBI with dementia, emphasizing the imaging techniques currently available in clinical practice along with some advances in medical knowledge.
Traumatic brain injury (TBI) represents a significant public health problem in modern societies. It is primarily a consequence of traffic-related accidents and falls. Other recently recognized causes include sports injuries and indirect forces such as shock waves from battlefield explosions. TBI is an important cause of death and lifelong disability and represents the most well-established environmental risk factor for dementia. With the growing recognition that even mild head injury can lead to neurocognitive deficits, imaging of brain injury has assumed greater importance. However, there is no single imaging modality capable of characterizing TBI. Current advances, particularly in MR imaging, enable visualization and quantification of structural and functional brain changes not hitherto possible. In this review, we summarize data linking TBI with dementia, emphasizing the imaging techniques currently available in clinical practice along with some advances in medical knowledge.
Traumatic brain injury (TBI) is a common clinical problem that represents a major
source of morbidity and mortality in the modern era. The most common causes of head
injury are motor vehicle accidents and falls. TBI is commonly classified as mild,
moderate or severe, depending on whether the injury causes unconsciousness, how long
unconsciousness lasts and the severity of symptoms. Although most TBIs are
classified as mild because they are not life-threatening, even a mild TBI can have
serious and long-lasting effects. One of the most feared long-term consequence of
TBI is dementia, since a number of epidemiologic studies have shown that
experiencing a TBI in early or midlife is associated with an increased risk of
dementia in later life.[1] Common
areas of cognitive impairment caused by TBI include memory, information processing
speed, attention and executive function, with many TBI patients experiencing
degradation in all four even when their TBIs have been classified as mild.[2] It has also been observed that
repetitive mild head trauma, as experienced by professional boxers, football and
hockey players, is associated with a high risk of chronic traumatic encephalopathy
(CTE) a type of dementia with distinctive clinical and pathologic features. The
recent recognition that a similar syndrome may occur in military personnel, who also
experience high rates of mild TBI, has rekindled interest in this
condition.[1]Long-term cognitive deficits may occur despite normal-appearing brain on conventional
neuroimaging studies, such as computed tomography (CT) and magnetic resonance (MR)
imaging. In this setting, advanced MR techniques, including susceptibility-weighted
imaging (SWI), diffusion-weighted imaging (DWI), perfusion-weighted imaging (PWI),
magnetization transfer MRI (MT), magnetic resonance spectroscopy (MRS), diffusion
tensor imaging (DTI) and functional blood oxygen level-dependent MRI (fMRI) may shed
light on subtle but important findings in TBI. Other promising neuroimaging tools
include positron emission tomography (PET), single photon emission tomography
(SPECT) and magnetoencephalography (MEG). Our aim was to review data linking TBI
with dementia and to summarize the brain-imaging techniques currently available in
clinical practice along with some future imaging trends.
DEFINITION/CLASSIFICATION
TBI occurs when an outside force hits the head hard enough to cause the brain to move
violently within the skull disrupting normal brain function. According to whether
the injury causes unconsciousness and how long unconsciousness lasts, brain injury
may be classified as mild (mTBI) when no loss of consciousness occurs or
unconsciousness lasts less than 30 minutes, moderate when unconsciousness lasts more
than 30 minutes and severe if unconsciousness lasts more than 24 hours. TBI can also
be classified using the Glasgow coma scale (GCS) as mild (GCS=13-15), moderate
(GCS=9-12) and severe (GCS<8). However, defining minor versus major head injuries
is complex. Some authors suggest major injury as worsening level of consciousness,
loss of consciousness for more than 5 min, focal neurological findings, seizure,
failure to improve in mental status over time, penetrating skull injuries, signs of
a basal or depressed skull fracture, and confusion or aggression on
examination.[3-8]Post-concussion syndrome (PCS) refers to a set of nonspecific symptoms that may last
for weeks, months, or years after a concussion. Its most common symptoms include
headache, dizziness, difficulty concentrating, irritability, and sleep problems.
Loss of consciousness is not required for a diagnosis of concussion or
post-concussion syndrome. In most patients, post-concussion syndrome symptoms occur
within the first seven to 10 days and resolve within three months but can persist
for a year or longer.Dementia is a loss of mental ability sufficiently severe to interfere with normal
activities of daily living, lasting more than six months, not present at birth and
not associated with a loss or alteration of consciousness. Indeed, dementia is not a
single disease but an umbrella term covering a wide range of medical conditions that
have in common a group of symptoms caused by gradual death of brain cells. The loss
of cognitive abilities that occurs with dementia leads to impairments in memory,
reasoning, planning and behavior. Brain changes that cause dementia may be
temporary, but are more often permanent and worsen over time, leading to increasing
disabilities and a shortened lifespan.[9]Chronic traumatic encephalopathy (CTE) is a progressive degenerative disease
associated with history of repetitive brain trauma including symptomatic concussions
and asymptomatic subconcussive impacts to the head. This type of dementia was
initially recognized in professional boxers by Harrison S. Martland in
1928,[10] who described a
group of signs and symptoms called dementia pugilistica. Currently
CTE can only be definitively diagnosed postmortem and is classified as a distinct
entity in the category of tauopathy. Tauopathies are characterized by dissociation
of tau proteins from microtubules, which are hyperphosphorylated and aggregate to
form neurofibrillary tangles (NFTs), a process that presumably serves as the
instigator of toxicity and cell death by unknown mechanisms. CTE has been confirmed
at autopsy in football, soccer, ice hockey, and other contact sports athletes who
have an inherent risk of subconcussive or concussive injuries.[1,11,12]
EPIDEMIOLOGY
An estimated 10 million people are affected annually by TBI worldwide.[13] However, this figure is likely
underestimated because it does not include patients with mTBI who frequently dismiss
their symptoms and never seek medical attention (25%) or those who are seen in
private clinics or by primary care physicians (14%) that do not report the clinical
findings.[14,15] The Centers for Disease Control
and Prevention (CDC) estimate that 1.7 million Americans annually experience TBI
severe enough to cause death or require emergency room care or hospitalization and
that 5.3 million (almost 2% of the population) are living with some degree of
TBI-related disabilities.[1]
According to the World Health Organization, TBI will surpass many diseases as the
major cause of death and disability by the year 2020.[13,16] Based on
the large number of known and likely unknown cases, traumatic brain injury has been
referred to as the "silent epidemic".[17] Recently, the public has become more aware of TBI through news
reports of sports injuries leading to long-term effects of repetitive trauma to the
brain as well as news reports about soldiers returning from Iraq and Afghanistan
with TBI which is now being called the "signature injury of war".[18,19] These patients further increase the number of unaccounted
cases of mild TBI since they do not seek medical attention in the belief that
admission of symptoms may jeopardize their careers.[20,21]It is estimated that 75-90% of all treated brain injuries are mild corresponding to
an expected incidence of 100-300/100,000 cases according to the WHO task
force.[22] It has been
proposed that as many as one in three mTBI victims have persistent long-term
cognitive deficits,[23,24] which can occur despite normal
results on conventional neuroimaging studies. Based on currently available data, a
rough calculation of how much of the population's burden of dementia is attributable
to TBI suggests a risk of dementia attributable to TBI of 5%-15%.[1,25]
ETIOLOGY
Leading causes of TBI in the general population include falls, motor vehicle
collisions, assaults, and sports-related injuries.[21] Falls are the leading cause of TBI in all ages.
Those aged 75 years and older have the highest rates of TBI-related hospitalization,
long-term cognitive changes, and death due to falls. Other recently recognized
causes of TBI are repetitive head trauma resulting from contact sports, and
combat-related head injuries seen in soldiers returning from war.[18] In addition, TBI can result from
bullet wounds or other injuries that penetrate the skull and brain.TBI is a heterogeneous group of injuries with complex relationships with the
mechanism of injury and timing of the forces impacting the skull and body. There are
two common assumptions regarding the etiology of mTBI. The first is that the frontal
and anterior cortices are vulnerable to neural contusion (Figure 1). The second is that linear and rotational forces act
on axon bundles leading to axonal injury[26-29] (Figures 2 and 3). After the initial injury, secondary mechanisms elicit biochemical,
metabolic and cellular changes over the course of minutes, days and
months.[30,31]
Figure 1
Patient with mild cognitive decline after moderate TBI. MR
Susceptibility-weighted imaging (SWI) axial images [A and B] show
frontal contusion and superficial siderosis seen as cortical low signal
intensity lines over the cortex due to subarachnoid hemorrhage.
Figure 2
DAI and subarachnoid hemorrhage after mild TBI. Axial SWI [A, B and C]
show multiple focal lesions involving the basal ganglia and the lobar
white matter at the gray-white matter interface. Note also the bilateral
subarachnoid hemorrhage particularly evident in A B C the left sylvian
fissure.
Figure 3
DAI involving the splenium of the corpus callosum after TBI. Axial
T2-weighted [A], FLAIR [B], post-contrast T1-weighted [C], SWI [D], DWI
[E] and ADC map [F] show high signal lesion T2-weighted [A] and FLAIR
[B] images, with no enhancement after gadolinium administration [C], low
signal on SWI [D] and restricted diffusion (high signal on DWI [E] and
low signal on ADC map). MRI is the modality of choice for assessing
suspected diffuse axonal injury even in patients with entirely normal CT
of the brain. Note also the bilateral subgaleal haematomas.
Patient with mild cognitive decline after moderate TBI. MR
Susceptibility-weighted imaging (SWI) axial images [A and B] show
frontal contusion and superficial siderosis seen as cortical low signal
intensity lines over the cortex due to subarachnoid hemorrhage.DAI and subarachnoid hemorrhage after mild TBI. Axial SWI [A, B and C]
show multiple focal lesions involving the basal ganglia and the lobar
white matter at the gray-white matter interface. Note also the bilateral
subarachnoid hemorrhage particularly evident in A B C the left sylvian
fissure.DAI involving the splenium of the corpus callosum after TBI. Axial
T2-weighted [A], FLAIR [B], post-contrast T1-weighted [C], SWI [D], DWI
[E] and ADC map [F] show high signal lesion T2-weighted [A] and FLAIR
[B] images, with no enhancement after gadolinium administration [C], low
signal on SWI [D] and restricted diffusion (high signal on DWI [E] and
low signal on ADC map). MRI is the modality of choice for assessing
suspected diffuse axonal injury even in patients with entirely normal CT
of the brain. Note also the bilateral subgaleal haematomas.Traumatic brain injury is the most well-established environmental risk factor for
dementia. Currently available data suggest: (I) sufficient evidence of an
association between moderate/severe TBI and dementia, with an increased risk of
dementia of between 2-and 4-fold for these patients; (II) limited evidence of an
association between mild TBI with loss of consciousness and dementia; (III) and
inadequate/insufficient evidence to determine whether an association exists between
mild TBI without loss of consciousness and dementia.[1,32] There is
no evidence that a single mild TBI episode increases dementia risk. However, as
stated before, it is accepted that multiple repetitive mTBIs, as observed in
professional boxers, retired professional football, hockey and soccer players and
other contact sports players, may have serious long-term consequences.[33] The risk of dementia in boxers
seems most closely tied to the number of rounds boxed, not to the number of times a
boxer was knocked out, suggesting that even repeated mild TBIs that do not cause
unconsciousness may increase dementia risk.[9] Additionally, it has been proven that a number of
sub-concussive events may be as damaging as a frank concussion.[34]
PATHOPHYSIOLOGY
TBI initiates an inflammatory cascade that results in the release of amino acids,
such as glutamate and aspartate, and free radicals that lead to tissue
damage.[35] Other potential
culprits include nitrous oxide, endogenous opioid peptides such as naloxone,
catecholamines, acetylcholine, thyrotropin-releasing hormone (TRH), lactate, and
adenosine.[36,37] Cytokines such as tumor necrosis
factor (TNF) and interleukins 1,6, and 8, have also been found to increase following
TBI.[38] PET, functional
MRI, MR spectroscopy, and SPECT, may play a crucial role in identifying the
concentrations and locations of some of these molecules in animal and human brains
following injury.[8]The diffuse axonal injury (DAI) which can occur after severe, moderate and mTBI is an
important neuropathological consequence of brain trauma. DAI involves a number of
abnormalities ranging from direct damage to the axonal cytoskeleton to secondary
damage from disruption of axoplasmic membrane transport, proteolysis, and
swelling.[39] For instance,
ionic imbalances, through an efflux of potassium and influx of sodium, lead to
calcium influx into cells resulting in mitochondrial damage and impaired oxidative
metabolism with lactate production.[16,40,41]Several investigators have studied the relationship between inheritance of the
apolipoprotein ε4 (APOE ε4) allele and dementia (particularly
Alzheimer disease) after TBI, with conflicting results. In a population-based study
in Northern Manhattan, New York[42]
a history of TBI and inheritance of an APOE ε4 allele were associated with a
10-fold increased risk of dementia while APOE ε4 in the absence of TBI
resulted in only a 2-fold increased risk of dementia. The study found no increased
risk of dementia due to TBI in the absence of APOE ε4. Similarly, in a
prospective study of World War II veterans,[43] there was a non-significant trend toward higher dementia
risk in APOE ε4 carriers. Conversely, in the MIRAGE study,[44] the influence of head injury on
the risk of dementia was greater among persons lacking APOE ε4 compared with
those having one or two APOE ε4 alleles.[1]
PATHOLOGY
In rodent models, TBI resulted in neurodegeneration and progressive brain atrophy
that continued for at least 1 year after injury.[1,45] Several proteins
associated with neurodegenerative disease in humans have also been demonstrated to
accumulate following experimental TBI in rodents. Amyloid precursor protein is
upregulated immediately after TBI and β-amyloid peptide accumulates over
weeks and months after trauma.[46-48] β-Secretase, presenilin 1,
and caspase 3 also accumulate for up to 6 months after injury.[47] In triple transgenic mice
expressing pathogenic mutations in amyloid precursor protein, pre-senilin 1 and tau,
TBI resulted in accumulations of intra-axonal β-amyloid peptide and
hyperphosphorylated tau which persisted for up to 1 week after injury.[49] These findings have led to the
hypothesis that β-amyloid peptide and tau accumulation are important
mechanisms in the long-term neurodegenerative effects of TBI. This hypothesis has
important therapeutic implications as recent developments in Alzheimer disease (AD)
therapeutics, such as anti-β-amyloid antibodies, inhibitors of β-
secretase or γ-secretase activity, or other amyloid- or tau-targeted
therapies[50,51] may have potential roles in the
management of TBI.[1]Additional evidence indicating that neurodegeneration after TBI shares some features
with AD has been noted on imaging studies. Cerebral atrophy after TBI is not diffuse
but rather regionally selective, and the regions that show the most prominent
atrophy after TBI, such as the hippocampus, amygdala, precuneus, and parietal and
frontal cortices, closely overlap with regions of predominant β-amyloid
deposition, decreased glucose uptake, and progressive atrophy in AD.[52] These findings may be related to
common molecular mechanisms shared between AD and TBI-related
neurodegeneration.[1,8] However, AD and CTE are distinct
entities. Recent studies in retired professional athletes who had sustained multiple
concussions and developed dementia, reported prominent tau-immunoreactive NFTs and
astrocytic tangles, but β-amyloid pathology was noted in less than half of
the cases.[1,11] There is also a characteristic distribution
pattern of NFTs unique to CTE. The NFTs tend to concentrate in the medial temporal
cortex, hippocampus and parahippocampal gyrus, thalamus, mammillary bodies,
amygdala, hypothalamus, and substantia nigra. The NFTs also preferentially
accumulate in the depths of sulci and surround small blood vessels and in the
ventricles in an irregular, patchy distribution. In the neocortices, NFTs
concentrate in superficial layers II and III, differing from AD in which NFTs
predominate in the deeper layers V and VI. Also unlike AD, there is a paucity of
neuritic plaques in CTE.[1,11]
CLINICAL FINDINGS
The severity of symptoms depends on whether the injury is mild, moderate or severe.
Symptoms often appear at the time of the injury or soon after, but sometimes may not
develop for days or weeks. In all levels of TBI, cognitive changes are among the
most common, long-lasting and disabling (Figure
4). The ability to learn and remember new information is often affected.
Other commonly affected thinking skills include the capacity to pay attention,
organize thoughts, plan effective strategies for completing tasks and activities,
and make sound judgments.[9]
Figure 4
Cognitive decline 8 weeks after TBI. Axial T1-weighted [A], T2-weighted
[B] and FLAIR [C] images show bilateral chronic subdural hematomas with
no midline shift.
Cognitive decline 8 weeks after TBI. Axial T1-weighted [A], T2-weighted
[B] and FLAIR [C] images show bilateral chronic subdural hematomas with
no midline shift.There is a misconception that loss of consciousness must occur to be characterized as
mTBI. As a result, many people with mTBI do not seek help and many health care
professionals do not recognize that mTBI has occurred.[16] Indeed, the term "mild TBI" is actually a misnomer
since serious short and long term effects are associated. Individuals with an
initial GCS score of 13-15 are acutely at risk for intracranial bleeding and diffuse
axonal injury[53] (Figure 2). Additionally, after a concussion, a
minority of patients have persistent disabling symptoms known as post-concussion
syndrome (PCS). The rates of PCS vary but most studies report that about 15% to 30%
of individuals with a history of a single concussion develop persistent symptoms
associated with the injury. The nature of symptoms in PCS may change over time and
acute symptoms are most commonly of a physical nature while persistent symptoms tend
to be predominantly psychological. Headache and dizziness usually occur immediately
after the injury but can also be long lasting. PCS is a clinical diagnosis that is
difficult to establish since most symptoms are similar to those experienced by
individuals diagnosed with depression, chronic pain, anxiety, or post-traumatic
stress disorder.[1,54] Some experts believe post-concussion symptoms are
caused by structural damage to the brain or disruption of neurotransmitter systems
resulting from the impact that caused the concussion. Others believe that
post-concussion symptoms are related to psychological factors.PCS should not be confused with CTE. Clinical symptoms of CTE are only beginning to
be understood. They are thought to include changes in mood (i.e. depression,
suicidality, apathy, anxiety), cognition (i.e. memory loss, executive dysfunction),
behavior (i.e. short fuse, aggression), and in some patients, motor disturbances
(i.e. difficulty with balance and gait). Differentiating between prolonged PCS and
CTE symptoms can be difficult.
DIAGNOSIS
The diagnosis of TBI in the acute setting is based on neurological examination and
neuroimaging tools such as CT and MR imaging. While CT may be critically important
in the first 24 hours to assess the immediate need for neurosurgical intervention,
MR imaging is more sensitive for detecting small and subtle abnormalities not
detected by CT.[19]In the chronic management of head trauma, imaging has several potential roles such as
identifying postoperative neurophysiological sequelae, evaluating the underlying
functional abnormalities associated with late complications of head trauma,
predicting long-term prognosis, guiding rehabilitation, and developing new therapies
to prevent secondary injury.[8,19]Mild TBI is difficult to diagnose because the brain often appears normal on
conventional CT and MR imaging. This lack of imaging evidence of brain injury in
mTBI has led clinicians to typically diagnose it on the basis of clinical and
cognitive symptoms, which are generally self-reported and are
non-specific.[53] The
symptoms may be the result of subtle neurological alterations that are beneath the
threshold of what can be detected using conventional neuroimaging
techniques.[1,19] Unlike PCS in which the diagnosis
is clinical, CTE diagnosis can only be made at brain autopsy.Research studies are currently examining whether neuroimaging can detect subtle
changes in axonal integrity and structural lesions that can occur in mTBI. Recently,
further progress in in-vivo diagnostic techniques has been made,
particularly with MR imaging advanced techniques. However, more research needs to be
done before any such techniques can be validated.[1,21,54,55]
IMAGING FINDINGS
MR imaging. MR imaging of morphometric abnormalities in patients with
mTBI has been extensively studied. Generalized brain atrophy is commonly reported
and seems to be a common finding in more severely affected patients.[56-64] Reductions in volume in specific brain regions have been
observed including in the hippocampus[65-68]
amygdalas,[63]
fornices,[58,68] thalamus,[63,67] and regions of the cingulate gyrus,[59,60,64,67] as well as enlargements of the lateral ventricles,
temporal horns and/or ventricular-to-brain ratio.[58,65,66,69] Reduced volume in subcortical gray matter regions[58] and an overall reduction in white
matter have also been reported.[57,60,70] Ding et al.[57] noted that the changes in white and gray matter over time
correlated with acute diffuse axonal injuries and that the latter predicted
post-injury cerebral atrophy.[19]DAI is an important consequence of TBI. DAI is usually diffuse, bilateral and
frequently involves the lobar white matter at the gray-white matter interface and
may be reversible (Figures 2 and 3). Although DAI is rarely fatal, it can result
in significant neurological impairment. The number of lesions correlates with poorer
outcomes and lesions in the supratentorial white matter, corpus callosum and corona
radiata correlate with a greater likelihood that the patient will remain in a
persistent vegetative state. Whereas hemorrhagic axonal injury can be seen on CT as
multiple foci of high attenuation, non-hemorrhagic injury can be missed. In fact, CT
is abnormal in less than half of all patients with DAI[8] (Figure 5).
Figure 5
DAI in a patient with severe TBI. Axial non-contrast CT [A and B] show
multiple hyperdense lesions varying in size involving primarily the
gray-white matter junction. Note that the appearance of DAI on CT
depends on whether or not the lesions are hemorrhagic. Subtle or
nonhemorrhagic DAI may be not detected on CT and such patients usually
have relatively normal CT scans with significant unexplained
neurological deficit.
DAI in a patient with severe TBI. Axial non-contrast CT [A and B] show
multiple hyperdense lesions varying in size involving primarily the
gray-white matter junction. Note that the appearance of DAI on CT
depends on whether or not the lesions are hemorrhagic. Subtle or
nonhemorrhagic DAI may be not detected on CT and such patients usually
have relatively normal CT scans with significant unexplained
neurological deficit.Susceptibility weighted imaging (SWI) has a six-fold greater ability to detect
hemorrhagic DAI than other MR imaging techniques.[71,72] This
technique is thus particularly appropriate for discerning micro-hemorrhages in TBI
as it is sensitive to bleeding where small and subtle lesions are not discernible
using other MR imaging techniques. This renders SWI particularly useful in the acute
and subacute stages following brain trauma[8,19] (Figure 6).
Figure 6
DAI after severe TBI (motor vehicle accident) well depicted on SWI. Axial
SWI [A, B and C} shows diffuse and bilateral lesions involving the basal
ganglia, lobar white matter, gray-white matter junction, corpus callosum
and the brainstem. SWI (or gradient echo sequences) are exquisitely
sensitive to blood products and the best MR sequences for DAI detection.
Note that when the DAI lesions are entirely nonhemorrhagic they will not
be detected on these sequences, but the will be visible as areas of high
FLAIR signal.
DAI after severe TBI (motor vehicle accident) well depicted on SWI. Axial
SWI [A, B and C} shows diffuse and bilateral lesions involving the basal
ganglia, lobar white matter, gray-white matter junction, corpus callosum
and the brainstem. SWI (or gradient echo sequences) are exquisitely
sensitive to blood products and the best MR sequences for DAI detection.
Note that when the DAI lesions are entirely nonhemorrhagic they will not
be detected on these sequences, but the will be visible as areas of high
FLAIR signal.Diffusion-tensor imaging (DTI) is a relatively new neuroimaging technique that is
sensitive to subtle changes in white matter fiber tracts and is capable of revealing
microstructural axonal injuries, which may be potentially responsible for persistent
post-traumatic symptoms.[1,19]The concept underlying DTI is that the local profile of the diffusion in different
directions provides important indirect information about the microstructure of the
underlying tissues. In the white matter, axonal membranes, myelin sheaths,
microtubules and neurofilaments restrict the movement of water. This restriction is
dependent on the direction of the axons (i.e. diffusion is not equal in all
directions). Water diffuses freely in directions parallel to axons but it is
restricted in directions perpendicular to axons which results in the magnitude of
the diffusion along axons being greater than the two perpendicular directions thus
leading to an elongated ellipsoidal shape of the diffusion tensor described as
"anisotropic." There are various ways that the shape and size of a diffusion
ellipsoid can be quantified but the two most common indices used are Fractional
Anisotropy (FA) for shape, and Mean Diffusivity (MD) for size. FA is a scalar
measure that ranges from 0 to 1, with 0 indicating complete isotropy meaning that
water diffuses equally in all directions and 1 depicting the most extreme
anisotropic scenario in which molecules are diffusing along a single axis.
Accordingly, in normal white matter FA should be close to 1 and reduced FA is
generally thought to reflect loss of white matter integrity. DTI, however, is
somewhat non-specific when using these parameters and it is not known whether
disruptions in FA and MD are the result of disturbances in axonal membranes, myelin
sheath, microtubules, neurofilaments, or other factors.Different DTI studies in TBI have shown that most of the abnormalities have a
systematic spatial distribution corroborating previous suggestions that anterior
regions of the brain are more vulnerable to post-traumatic abnormalities.[54,73-75]Different studies support the hypothesis that acute mTBI is associated with elevated
anisotropy values and chronic mTBI with depressed anisotropy.[54,76,77] However, some
studies have reported both trauma-related decreases and increases in FA,
particularly in the subacute phase post-injury while many others have reported that
FA values increase in both acute and chronic phases of injury.[21] One possibility for the increase
in FA acutely is that MR diffusion-based measurements are not only sensitive to
white matter microstructure but additionally are affected in the acute stage by
inflammation, secondary injury (ischemia, cerebral hypoxia, and cerebral edema)
and/or compensatory mechanisms.[76,77] Chronically though, residual
damage of white matter may lead to decreased anisotropy. Whatever the causative
mechanism is, poor neuropsychological performance seems to be associated with high
anisotropy scores immediately after injury and with low anisotropy in the chronic
phase.[54]More specific measures to further delineate the biological meaning of alterations in
white matter integrity are under investigation including Mode,[78] which more precisely defines the
shape of the diffusion tensor (useful in distinguishing the anatomy of fiber tracts,
including distinguishing fiber crossings from pathology); Inter-Voxel
Coherence,[79] which
measures how similar anisotropic tensors are in neighboring voxels and is useful for
measuring anomalies in macroscopic axonal organization within the tract of interest,
and Axial and Radial Diffusivity which are purported to measure axonal and myelin
pathology, respectively. Additional approaches include the free-water
model[80] by which it is
possible to explicitly estimate the volume of extracellular water, a measure that is
sensitive to vasogenic edema and therefore likely specific to neuro-inflammation;
Multi-shell diffusion imaging which is a new approach where DWI is acquired at
multiple b-values in the same session providing additional microstructural
information about the organization of white and gray matter; and kurtosis which is a
measure of the deviation from the diffusion tensor model (Gaussian diffusion) and
thus complements the other measures derived from the tensor model.[19] Other methods for resolving
crossing fibers include the neurite orientation dispersion and density imaging
model,[81] Q-ball
imaging[82] and constrained
spherical deconvolution.[83] Further
studies are required to determine which method is the best.[21]A normative atlas of DTI-derived measures that depict anatomical variations in
healthy controls can also be created so that individual cases may then be compared
to discern the pattern of pathology.[19]In summary, DTI is a promising neuroimaging technique that may help to identify
axonal injury after mTBI, however, its role in routine clinical practice has not yet
been establishedAnother promising technique is MR spectroscopy (MRS), which is able to quantify
different brain metabolites including N-acetylaspartate (NAA) for neuronal
integrity, creatine (Cr) for cellular energy/attenuation, choline (Cho) for membrane
turnover, myoinositol an osmotic and gliosis marker, and lactate for anaerobic
metabolism. NAA, creatinine, choline, and myoinositol seem to be sensitive to
neuronal injury in DAI. In mild TBI, the most common finding is a widespread
reduction in gray matter and white matter NAA[21,56,84-87] and
several investigators have found that lower NAA to creatine ratios correlate with
poorer clinical outcomes.[8,88] Studies of MR spectroscopy in
chronic mild TBI have found reductions in NAA in the splenium of the corpus
callosum,[89] centrum
semiovale,[90] and frontal
white matter.[91] Chemical shift
imaging[92,93] and whole-brain NAA studies[92] have also demonstrated NAA
reductions in white matter. However, disparity exists between studies in the
quantification of Cho. Some studies have found increased Cho in various regions in
the brain parenchyma,[86,92,94] while others have reported the absence of statistical
changes in Cho.[87,93,95] Changes
found in Cho, a marker for cellular proliferation and/or tissue damage may reflect
diffuse axonal injury.[90,92] In the acute phase of head injury,
choline-containing metabolites may be released as a result of shear injuries and
damage to both cell membranes and myelin.[96] In chronic brain injury, the mechanism for increased Cho is
more likely to be related to diffuse glial proliferation, as corroborated by
elevated myoinositol that persists for months after injury.[97] Recent studies have shown changes
in Cr.[95,98] If Cr is affected by mild TBI, metabolite ratio
measurements are not accurate because it is difficult to assess whether these
changes are due to the metabolite of interest or to Cr. There is significant
heterogeneity in the literature and further research is needed to validate this
technique for routine clinical use.[21]MRS and DTI are complimentary given the biochemical and structural focus of each
modality. However, few studies have utilized both together. In severe head injury,
the combination of these two modalities provides greater diagnostic accuracy for
predicting outcome one year following injury[99] than either MRS or DTI alone. It is likely that this same
combination could also provide greater sensitivity to subtle changes in
mTBI.[19]Different studies have used magnetization transfer MRI (MT) to detect white matter
abnormalities in different diseases. Through MT, a magnetization transfer ratio can
be derived and used quantitatively to measure the structural integrity of tissues.
MT changes have been found to be more sensitive than T2-weighted MR imaging in
detecting histologic axonal damage in animal models.[100,101]
Bagley et al.[102] found
associations between MT abnormalities and neurological deficits.[8]Brain perfusion in patients with TBI has been done using different techniques,
including stable xenon-enhanced CT, single-photon emission CT (SPECT), PET,
perfusion CT, and perfusion-weighted MR imaging (dynamic susceptibility contrast and
arterial spin-labeling).[21]
Perfusion-weighted MR imaging is difficult to obtain in the acute setting due to
patient contraindications but is an attractive imaging technique for the subacute
and chronic phases especially because it can be combined with other MR imaging
sequences sensitive to TBI lesions.[21] In patients with mild TBI and normal conventional brain
imaging, perfusion-imaging studies have shown scattered deficits, which correlate
significantly with neuropsychological and neurocognitive impairments as well as
posttraumatic amnesia (Figure 7). The potential
benefits of perfusion imaging in the clinical management of patients with severe TBI
have yet to be evaluated. However, patients with altered brain perfusion may be
considered for more aggressive and early treatments to prevent intracranial
hypertension, whereas patients with preserved brain perfusion may benefit from less
invasive treatment. The majority of perfusion studies have involved only limited
numbers of patients and further research is required to validate their findings and
determine how relevant they are in the management of individual patients with
TBI.[21]
Figure 7
DAI involving the basal ganglia and gray-white matter junction. Axial CT
[A], T2 GRE [B] and DWI [C] show hemorrhagic DAI lesions. Perfusion
(dynamic susceptibility contrast) MR imaging cerebral blood volume (CBV)
[D], cerebral blood flow (CBF) [E], mean transit time (MTT) [F], and
time to peak (TTP) [G] maps show low perfusion at the level of the basal
ganglia.
DAI involving the basal ganglia and gray-white matter junction. Axial CT
[A], T2 GRE [B] and DWI [C] show hemorrhagic DAI lesions. Perfusion
(dynamic susceptibility contrast) MR imaging cerebral blood volume (CBV)
[D], cerebral blood flow (CBF) [E], mean transit time (MTT) [F], and
time to peak (TTP) [G] maps show low perfusion at the level of the basal
ganglia.Blood oxygen level-dependent (BOLD) fMRI methods for investigating TBI have utilized
task-based methods, particularly working memory paradigms. Task- based methods
require participation of patients to help identify activation of brain regions
thought to drive or be associated with task performances. Task-free resting-state
BOLD fMRI techniques have also been used in this setting with the advantage of being
able to evaluate distributed whole-brain networks without requiring overt behavioral
output from subjects.[21] Functional
MRI studies have found persistent changes in the brain activation patterns of mild
TBI patients compared with controls when given various working memory
tasks.[8,74] Additionally, a recent fMRI meta-analysis
demonstrated a frontal vulnerability to mTBI as determined by decreased signal in
the prefrontal cortex compared to controls. However, there is currently insufficient
evidence that fMRI based on BOLD techniques are useful in the routine clinical
diagnosis and/or prognosis of TBI.[21]PET measures cerebral metabolism using different tracers, most commonly
18F-fluorodeoxyglucose (18F-FDG), an analogue of glucose. 18F-FDG measures regional
glucose uptake, which should correspond to neuronal viability. PET can also be used
in patients with DAI to determine the extent of damage and prognosis since DAI
results in diffuse hypometabolism.[103,104] The major
limitation of PET imaging is that it cannot distinguish between functional
abnormalities associated or unassociated with structural damage. In general, studies
have found that cerebral dysfunction can extend far beyond the boundary of
anatomical lesions and may even appear in locations remote from the trauma. Alavi et
al.[103] found that GCS
scores of 13 and lower were associated with whole brain hypometabolism on 18F-FDG
PET. Additionally, areas of PET cerebral hypometabolism that have no correlates on
conventional CT or MRI, are associated with neurological and behavioral
dysfunction.[105,106] Moreover, some of these areas
can develop structural abnormalities such as encephalomalacia and atrophy on CT.
However, PET imaging can also disclose other potentially confounding
neuropsychiatric conditions such as depression or drug induced effects.[8]SPECT can detect abnormalities in cerebral blood flow (CBF). However, it is not
always clear whether the abnormalities observed on SPECT correspond to direct or
indirect injuries or possibly abnormalities from prior trauma or other
neuropsychiatric conditions. CBF abnormalities are commonly seen in mild TBI
patients with chronic symptoms even when no structural damage is apparent.[8,107]Very few PET and SPECT studies to date have gone beyond CBF and metabolic mapping to
incorporate specific ligands for exploring TBI-related changes. Recent PET amyloid
imaging suggests that amyloid levels rise in persons with TBI.[36] A small study with a combined
amyloid tau tracer showed higher levels in patients with TBI.[37] Beta amyloid deposition, while
seen in 40%- 45% of chronic traumatic encephalopathy, is not as common as tau
accumulation.[21,108]Only a few studies have used MEG to evaluate the effects of TBI, therefore, more work
is necessary to define the utility and capabilities of this imaging
technique.[21]
BIOMARKERS FOR TBI
Over the last decade, there have been numerous studies exploring promising biomarkers
of TBI. Despite the large number of publications on this subject there is still no
FDA-approved biomarkers for clinical use and further research is needed to introduce
them into the clinical setting.[16]
BIOMARKERS OF ASTROGLIAL INJURY
S100β is considered a marker of astrocyte injury or death. Elevated
S100β levels in serum have been associated with increased incidence of post
concussive syndrome and cognitive deficits.[6] However, there is a concern about the specificity of
S100β and its utility in the setting of multiple trauma remains controversial
since it is also elevated in traumapatients without head injuries.[16,109,110]Glial fibrillary acidic protein (GFAP) might be a useful marker for various types of
brain damage including neurodegenerative disorders, stroke, and severe
TBI.[109,111,112] In a
study by Papa et al. in 2012,[113]
GFAP was detectable in serum less than 1 hour after a concussion and was able to
distinguish concussion patients from other traumapatients without head
injury.[16]
BIOMARKERS OF NEURONAL INJURY
Neuron-specific enolase (NSE) has been shown be elevated after cell injury. In the
setting of DAI in severe TBI, levels of NSE at 72 hours after injury have shown an
association with unfavorable outcomes.[114] One of the limitations of NSE is the occurrence of
false-positive results in the setting of hemolysis.[16]A promising candidate biomarker for TBI currently under investigation is ubiquitin
C-terminal hydrolase-L[1] (UCH- L1).
Clinical studies in humans with severe TBI have confirmed that the UCH-L[1] protein is significantly elevated in
human cerebrospinal fluid (CSF),[115] is detectable very early after injury, and remains
significantly elevated for at least 1 week post-injury.[115] More recently, UCH-L[1] was detected in the serum of mild and moderate TBI
patients within one hour of injury.[113] Serum levels of UCH-L[1] discriminated concussion patients from uninjured and
non-head-injured trauma control patients that had orthopedic injuries or motor
vehicle trauma without head injury.
BIOMARKERS OF AXONAL INJURY
Alpha-II spectrin (280 kDa) is the major structural component of the cortical
membrane cytoskeleton and particularly abundant in axons, and presynaptic terminals
of spectrin breakdown products (SBDPs) have been reported in the cerebrospinal fluid
(CSF) of adults with severe TBI and shown a significant relationship with severity
of injury and clinical outcome.[16,111,116-118]Tau is an intracellular, microtubule-associated protein that is highly enriched in
axons and involved with assembling axonal microtubule bundles and participating in
anterograde axoplasmic transport. Because tau is preferentially located in the axon,
tau lesions are apparently related to axonal disruption.[16]Neurofilaments are heteropolymeric components of the neuron cytoskeleton that consist
of a 68-kDa light neurofilament subunit (NF-L) backboned with either 160-kDa medium
(NF-M) or 200-kDa heavy subunit (NF-H) side arms. After TBI, calcium influx into the
cells contributes to a cascade of events that activates calcineurin, a
calcium-dependent phosphatase that dephosphorylates neurofilament side arms,
presumably contributing to axonal injury.[26] Phosphorylated NF-H has been found to be elevated in the
CSF of adult patients with severe TBI compared with controls.[119]Although research in the field of TBI biomarkers has increased exponentially over the
past 20 years, most studies have focused on severe TBI rather than on mTBI. Because
more than 80% of patients have mTBI there is a need to explore biomarkers in this
population.[16]
OUTCOME
Dementia varies widely depending on the cause, age at diagnosis and coexisting health
conditions. Post-traumatic dementia is a progressive disorder that worsens over
time. Functional outcome depends on how many neurons are preserved after injury.
However, the location of damage and the ability of existing neurons to reorganize
their connections to recover function are also critical in determining
outcomes.[8]Aside from obvious cases of devastating injuries, a consistent relationship between
MRI lesions and clinical or neuropsychological outcomes has not been
demonstrated.[8] In fact,
neither CT nor MR imaging findings predict neurocognitive deficits shortly after
injury or at 1-year follow-up. Thus, early imaging findings are not predictive of
clinical outcome.[120]SPECT appears to be better than CT or MR imaging for determining long-term prognosis.
A negative initial SPECT scan after trauma strongly predicts a favorable clinical
outcome[121] whereas
abnormal SPECT is predictive of neuro-psychological deficits.[122] However, no consistent
correlation between SPECT abnormalities and neuropsychological test scores has been
established.[123] Because
MR imaging detects lesions missed by SPECT and vice versa, a combination of MR
imaging and SPECT may be best for determining prognosis.[8]Additionally, by combining different biomarkers from blood with MR imaging biomarkers
it may be possible to delineate specific types of brain injury involved in mTBI as
well as how they change over time and what the evolution of secondary damage or
progression of different types of injuries is over time.[19]
CONCLUSION
There is no known strategy to reduce the possible long-term risks of dementia after a
moderate or severe TBI, repeated mild TBIs or even after sub-concussive events, but
is important to note that not all individuals who experience head injury develop
dementia.New advanced imaging tools are particularly important for investigating brain
pathology in post-traumatic dementia where conventional MR and CT imaging have been
found to be insufficient. However, these new techniques are still in the research
stage and further investigations are needed before introducing them into clinical
routine.
Authors: T W McAllister; A J Saykin; L A Flashman; M B Sparling; S C Johnson; S J Guerin; A C Mamourian; J B Weaver; N Yanofsky Journal: Neurology Date: 1999-10-12 Impact factor: 9.910
Authors: Ann C McKee; Brandon E Gavett; Robert A Stern; Christopher J Nowinski; Robert C Cantu; Neil W Kowall; Daniel P Perl; E Tessa Hedley-Whyte; Bruce Price; Chris Sullivan; Peter Morin; Hyo-Soon Lee; Caroline A Kubilus; Daniel H Daneshvar; Megan Wulff; Andrew E Budson Journal: J Neuropathol Exp Neurol Date: 2010-09 Impact factor: 3.685
Authors: Varanavasi Govindaraju; Grant E Gauger; Geoffrey T Manley; Andreas Ebel; Michele Meeker; Andrew A Maudsley Journal: AJNR Am J Neuroradiol Date: 2004-05 Impact factor: 3.825
Authors: Vivian Hook; Michael Yoon; Charles Mosier; Gen Ito; Sonia Podvin; Brian P Head; Robert Rissman; Anthony J O'Donoghue; Gregory Hook Journal: Biochim Biophys Acta Proteins Proteom Date: 2020-04-17 Impact factor: 3.036